New daily pill aims to tame severe eosinophilic asthma

NCT ID NCT07323654

Recruiting now Disease control Sponsor: Kymera Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 27 times

Summary

This study tests an oral medication called KT-621 in adults with moderate to severe eosinophilic asthma that is not well controlled by current treatments. The goal is to see if the drug improves lung function and asthma control, and to check its safety. About 264 participants will receive either KT-621 or a placebo pill daily for several weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Kymera Investigative Site
RECRUITING

Long Beach, California, 90815, United States
Kymera Investigative Site
RECRUITING

Northridge, California, 91324, United States
Kymera Investigative Site
RECRUITING

Redding, California, 96001, United States
Kymera Investigative Site
RECRUITING

Upland, California, 91786, United States
Kymera Investigative Site
RECRUITING

Loxahatchee Groves, Florida, 33470, United States
Kymera Investigative Site
RECRUITING

Miami, Florida, 33126, United States
Kymera Investigative Site
RECRUITING

Miami, Florida, 33173, United States
Kymera Investigative Site
RECRUITING

Tampa, Florida, 33607, United States
Kymera Investigative Site
RECRUITING

East Point, Georgia, 30344, United States
Kymera Investigative Site
RECRUITING

Iowa City, Iowa, 52242, United States
Kymera Investigative Site
RECRUITING

Chapel Hill, North Carolina, 27517, United States
Kymera Investigative Site
RECRUITING

Toledo, Ohio, 43617, United States
Kymera Investigative Site
RECRUITING

Edmond, Oklahoma, 73034, United States
Kymera Investigative Site
RECRUITING

Clackamas, Oregon, 97015, United States
Kymera Investigative Site
RECRUITING

Pittsburgh, Pennsylvania, 15241, United States
Kymera Investigative Site
RECRUITING

North Charleston, South Carolina, 29406, United States
Kymera Investigative Site
RECRUITING

Rock Hill, South Carolina, 29732, United States
Kymera Investigative Site
RECRUITING

Chattanooga, Tennessee, 37403, United States
Kymera Investigative Site
RECRUITING

Dallas, Texas, 75209, United States
Kymera Investigative Site
RECRUITING

McKinney, Texas, 75069, United States
Kymera Investigative Site
RECRUITING

Belgrade, 11000, Serbia
Kymera Investigative Site
RECRUITING

Kamenitz, 21204, Serbia
Kymera Investigative Site
RECRUITING

Užice, 31000, Serbia
Kymera Investigative Site
RECRUITING

Spišská Nová Ves, Slovakia
Kymera Investigative Site
RECRUITING

Bedford, MK40 2FG, United Kingdom
Kymera Investigative Site
RECRUITING

Leicester, United Kingdom
Kymera Investigative Site
RECRUITING

London, United Kingdom

Conditions

Explore the condition pages connected to this study.

EOSINOPHILIC ASTHMA